BCHE
EstablishedBCHE is a plasma enzyme whose deficiency causes prolonged paralysis after certain anesthesia drugs.
This enzyme breaks down a common anesthesia drug. People with a genetic variant that lowers this enzyme can experience unusually long paralysis after receiving that drug during surgery — sometimes for hours — which is important for anesthesiologists to know in advance if possible.
Butyrylcholinesterase (BChE), also called pseudocholinesterase, is a liver-produced plasma enzyme that metabolizes certain drugs, most notably the anesthesia muscle relaxant succinylcholine. It is genetically distinct from acetylcholinesterase (AChE).
Patients with inherited BCHE gene variants that reduce enzyme activity are at risk of prolonged, sometimes hours-long, paralysis and apnea after receiving succinylcholine or mivacurium during anesthesia, occurring in roughly 1 in 1,800 anesthesias.
Diagnosis is typically made biochemically (measuring enzyme activity, dibucaine number) after a clinical episode of prolonged paralysis; genetic BCHE testing exists but is not yet standard proactive practice, usually only offered reactively after an affected patient or family member has already had an episode.
Once identified, patients should avoid succinylcholine and mivacurium in future anesthesia, and family members are encouraged to undergo testing given the autosomal recessive inheritance pattern.
One of the earliest-known pharmacogenomic drug-gene interactions; genetic testing remains underutilized.
- Nguyen, et al. (2025). Hereditary Pseudocholinesterase Deficiency and Succinylcholine: Historical Perspective. Pharmacotherapy.
- Sasaki, et al. (2020). Genetic Testing for BCHE Variants Identifies Patients at Risk of Prolonged Neuromuscular Blockade. PMC.